Physiomics plc has confirmed a significant board overhaul following the successful passage of all resolutions at its recent general meeting.
The changes see the appointment of three new directors: Michael Whitlow joins as Executive Director, bringing over two decades of experience in financing and scaling early-stage businesses. Nicholas Tulloch has been appointed Non-Executive Chair, with a background spanning more than 20 years advising companies across UK capital markets. Meanwhile, Ian Bagnall joins as Non-Executive Director, contributing extensive expertise in corporate finance and operational leadership.
As part of the restructuring, Dr. Peter Sargent, Shalabh Kumar, and Dr. Tim Corn have stepped down from the board.
The new leadership team also brings meaningful shareholder alignment. Whitlow currently holds approximately 12.36% of the company’s issued share capital, while Bagnall owns around 3.31%, positioning both as influential stakeholders in the company’s future direction.
Overall, the board changes mark a strategic reset, with increased emphasis on capital markets expertise and growth financing capabilities.
